Author:
Sandén Emma,Khazaei Somayeh,Tryggvadottir Helga,Borgquist Signe,Isaksson Karolin,Jirström Karin,Jernström Helena
Abstract
AbstractHuman epidermal growth factor receptor 2 (HER2) status in breast cancer is routinely determined through immunohistochemistry (IHC) and/or in situ hybridisation (ISH) performed on whole tissue sections (WS). The purpose was to evaluate whether a gene protein assay (GPA) combining IHC with ISH, performed on breast cancer tissue microarray (TMA), is suitable for large-scale retrospective HER2 status evaluation. TMAs from 606 tumours from a Swedish population-based cohort (2005–2012) were stained with GPA. GPA IHC on TMA yielded weaker staining than IHC on WS during routine pathological assessment (86.0% agreement). However, final HER2 status agreement between GPA on TMA and WS based on both IHC and ISH was 97.7%. Only 14 tumours were discordant and one tumour with IHC score 1+ on both TMA and WS was HER2 amplified on TMA. In conclusion, GPA on TMA is suitable for large-scale retrospective evaluation of HER2 status.
Funder
Cancerfonden
Medicinska Fakulteten, Lunds Universitet
Fru Berta Kamprads Stiftelse
Region Skåne
Skånes universitetssjukhus
Publisher
Springer Science and Business Media LLC
Subject
Cell Biology,Molecular Biology,General Medicine,Pathology and Forensic Medicine
Reference16 articles.
1. Escriva-de-Romani S, Arumi M, Bellet M, Saura C (2018) HER2-positive breast cancer: current and new therapeutic strategies. Breast 39:80–88. https://doi.org/10.1016/j.breast.2018.03.006
2. Regionala cancercentrum (2018) Swedish guidelines concerning breast pathology (Kvalitetsdokument för patologi). Available from: http://www.svfp.se/foreningar/uploads/L15178/kvast/brostpatologi/KVASTbrostcancer2018.pdf. Accessed 2019-11-01
3. Downs-Kelly E, Pettay J, Hicks D, Skacel M, Yoder B, Rybicki L, Myles J, Sreenan J, Roche P, Powell R, Hainfeld J, Grogan T, Tubbs R (2005) Analytical validation and interobserver reproducibility of EnzMet GenePro: a second-generation bright-field metallography assay for concomitant detection of HER2 gene status and protein expression in invasive carcinoma of the breast. Am J Surg Pathol 29(11):1505–1511. https://doi.org/10.1097/01.pas.0000172294.67409.4f
4. Varga Z, Tubbs RR, Moch H (2014) Concomitant detection of HER2 protein and gene alterations by immunohistochemistry (IHC) and silver enhanced in situ hybridization (SISH) identifies HER2 positive breast cancer with and without gene amplification. PLoS One 9(8):e105961. https://doi.org/10.1371/journal.pone.0105961
5. Nitta H, Kelly BD, Allred C, Jewell S, Banks P, Dennis E, Grogan TM (2016) The assessment of HER2 status in breast cancer: the past, the present, and the future. Pathol Int 66(6):313–324. https://doi.org/10.1111/pin.12407
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献